Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)
As one of the world's largest manufacturers of generic medicines, Teva makes treatments more affordable and accessible - reaching nearly 200 million patients every day. With its vast global presence, the Company views its decarbonization activities as an opportunity to make a significant impact on the environment.
The targets validated by SBTi are to reduce absolute scope 1 and 2 GHG emissions by
Scope 1 and 2 target is integrated into Teva’s financing strategy, as part of the Company’s
“The health of our planet is inherently linked to the health of those who inhabit it, and health is what we do at Teva,” said
Protecting the environment is part of Teva’s environmental, social and governance (ESG) strategy, and inherent to the Company’s culture. Progress toward these goals is a result of efforts across Teva’s business, such as converting some manufacturing sites to
Teva will continue to share progress against its environmental targets and externally verify its performance in the Company’s annual ESG Progress Report.
About Teva
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to impact and effectively execute on our social, economic, environment and governance related strategies and goals; environmental risks; failure to comply with applicable environmental laws and regulations worldwide; our ability to satisfy the targets set forth in our sustainability-linked senior notes and in other sustainability-linked financing instruments that we may issue; the impact of ESG issues on our business; and consequences of climate change; our ability to successfully compete in the marketplace; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to obtain sufficient participation of plaintiffs for the proposed nationwide settlement to take effect; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005389/en/
IR
(267) 468-4475
972 (3) 914-8262
PR
(973) 658-0237
972 (3) 906-2645
Source: